Convalescent plasma as a potential therapy for COVID-19

The Lancet Infectious Diseases

Volumn 20, Issue 4, 2020, Pages 398-400

  Chen, Long ^a,b,c   Xiong, Jing ^a,b,c   Bao, Lei ^a,b,c   Shi, Yuan ^a,b,c  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b Center for Child Development and Disorders   (China)

^c CHILDREN S HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN;

CONVALESCENT PLASMA; CORONAVIRINAE; CORONAVIRUS DISEASE 2019; CORONAVIRUS INFECTION; HUMAN; HUMORAL IMMUNITY; META ANALYSIS (TOPIC); MORTALITY; NONHUMAN; NOTE; PLASMA TRANSFUSION; PRIMARY IMMUNE RESPONSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; SURVIVAL RATE; VIRAL CLEARANCE; VIRUS IMMUNITY; VIRUS LOAD; BETACORONAVIRUS; PANDEMIC; VIRUS PNEUMONIA;

BETACORONAVIRUS; CORONAVIRUS INFECTIONS; HUMANS; IMMUNOGLOBULINS; PANDEMICS; PNEUMONIA, VIRAL;

EID: 85082188246     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(20)30141-9     Document Type: Note

References (14)

1. Holshue, ML, DeBolt, C, Lindquist, S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med, 2020 published online Jan 31. https://doi.org/10.1056/NEJMoa2001191.
2. Lai, ST, Treatment of severe acute respiratory syndrome. Eur J Clin Microbiol Infect Dis 24 (2005), 583–591.
3. Soo, YO, Cheng, Y, Wong, R, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect 10 (2004), 676–678.
4. Cheng, Y, Wong, R, Soo, YO, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 24 (2005), 44–46.
5. WHO. Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks. http://apps.who.int/iris/rest/bitstreams/604045/retrieve, 2014. (Accessed 20 February 2020)
6. Arabi, Y, Balkhy, H, Hajeer, AH, Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. Springerplus, 4, 2015, 709.
7. Hung, IF, To, KK, Lee, CK, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 52 (2011), 447–456.
8. Hung, IFN, To, KKW, Lee, CK, et al. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest 144 (2013), 464–473.
9. Mair-Jenkins, J, Saavedra-Campos, M, Baillie, JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 211 (2015), 80–90.
10. Luke, TC, Kilbane, EM, Jackson, JL, Hoffman, SL, Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?. Ann Intern Med 145 (2006), 599–609.
11. Schoofs, T, Klein, F, Braunschweig, M, et al. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science 352 (2016), 997–1001.
12. Lu, CL, Murakowski, DK, Bournazos, S, et al. Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. Science 352 (2016), 1001–1004.
13. WHO. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf, 2020. (Accessed 20 February 2020)
14. Clark, DR, Jonathan, EM, JKB. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet, 2020 published online Feb 7. https://doi.org/10.1016/S0140-6736(20)30317-2.